286 related articles for article (PubMed ID: 23783268)
1. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
2. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
3. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
4. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
5. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
6. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Kawabata M; Yokoyama Y; Sasano T; Hachiya H; Tanaka Y; Yagishita A; Sugiyama K; Nakamura T; Suzuki M; Isobe M; Hirao K
J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
8. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
10. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
11. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.
Dager WE; Gosselin RC; Kitchen S; Dwyre D
Ann Pharmacother; 2012 Dec; 46(12):1627-36. PubMed ID: 23232017
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran monitoring made simple?
Eikelboom JW; Weitz JI
Thromb Haemost; 2013 Sep; 110(3):393-5. PubMed ID: 23884303
[No Abstract] [Full Text] [Related]
15. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
He S; Wallèn H; Bark N; Blombäck M
J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
[TBL] [Abstract][Full Text] [Related]
16. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran assessment in patients with acute complications using routine coagulation assays.
Stang L; Nahirniak S; Butcher K; Szkotak AJ
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):426-34. PubMed ID: 24637695
[TBL] [Abstract][Full Text] [Related]
18. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
Kate M; Szkotak A; Witt A; Shuaib A; Butcher K
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1351-5. PubMed ID: 24406026
[TBL] [Abstract][Full Text] [Related]
19. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
